Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 2
2011 1
2013 1
2020 3
2021 3
2022 2
2023 4
2024 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
[Delegation of medical tasks in rheumatology].
Krause A, Schuch F, Braun J, Gauler G, Hoeper K, Krüger K, Wallhäuser M, Voormann AJ. Krause A, et al. Among authors: gauler g. Z Rheumatol. 2020 Mar;79(2):123-131. doi: 10.1007/s00393-020-00760-z. Z Rheumatol. 2020. PMID: 32100116 German.
Analysis of the shorter drug survival times for Janus kinase inhibitors and interleukin-17 inhibitors compared with tumor necrosis factor inhibitors in a real-world cohort of axial spondyloarthritis patients - a retrospective analysis from the RHADAR network.
Strunz PP, Englbrecht M, Risser LM, Witte T, Froehlich M, Schmalzing M, Gernert M, Schmieder A, Bartz-Bazzanella P, von der Decken C, Karberg K, Gauler G, Wurth P, Späthling-Mestekemper S, Kuhn C, Vorbrüggen W, Heck J, Welcker M, Kleinert S. Strunz PP, et al. Among authors: gauler g. Rheumatol Int. 2024 Oct;44(10):2057-2066. doi: 10.1007/s00296-024-05671-9. Epub 2024 Aug 13. Rheumatol Int. 2024. PMID: 39136784 Free PMC article.
Drug survival superiority of tumor necrosis factor inhibitors and interleukin-17 inhibitors over Janus kinase inhibitors and interleukin-12/23 inhibitors in German psoriatic arthritis outpatients: retrospective analysis of the RHADAR database.
Strunz PP, Englbrecht M, Risser LM, Witte T, Froehlich M, Schmalzing M, Gernert M, Schmieder A, Bartz-Bazzanella P, von der Decken C, Karberg K, Gauler G, Wurth P, Späthling-Mestekemper S, Kuhn C, Vorbrüggen W, Heck J, Welcker M, Kleinert S. Strunz PP, et al. Among authors: gauler g. Front Immunol. 2024 May 23;15:1395968. doi: 10.3389/fimmu.2024.1395968. eCollection 2024. Front Immunol. 2024. PMID: 38846940 Free PMC article.
A Real-World Rheumatology Registry and Research Consortium: The German RheumaDatenRhePort (RHADAR) Registry.
Kleinert S, Bartz-Bazzanella P, von der Decken C, Knitza J, Witte T, Fekete SP, Konitzny M, Zink A, Gauler G, Wurth P, Aries P, Karberg K, Kuhn C, Schuch F, Späthling-Mestekemper S, Vorbrüggen W, Englbrecht M, Welcker M; RHADAR Group. Kleinert S, et al. Among authors: gauler g. J Med Internet Res. 2021 May 20;23(5):e28164. doi: 10.2196/28164. J Med Internet Res. 2021. PMID: 34014170 Free PMC article.
[Delegation of medical tasks in rheumatology].
Krause A, Krüger K, Braun J, Gauler G, Hoeper K, Schuch F, Voormann AJ. Krause A, et al. Among authors: gauler g. Z Rheumatol. 2020 Oct;79(Suppl 2):47-48. doi: 10.1007/s00393-020-00862-8. Z Rheumatol. 2020. PMID: 32910206 German. No abstract available.
Impairment in cognitive function in patients with axial spondyloarthritis and psoriatic arthritis.
Kleinert S, Schuch F, Rapp P, Ronneberger M, Wendler J, Sternad P, Popp F, Bartz-Bazzanella P, von der Decken C, Karberg K, Gauler G, Wurth P, Späthling-Mestekemper S, Kuhn C, Englbrecht M, Vorbrüggen W, Adler G, Welcker M. Kleinert S, et al. Among authors: gauler g. Rheumatol Int. 2023 Jan;43(1):89-97. doi: 10.1007/s00296-022-05248-4. Epub 2022 Nov 28. Rheumatol Int. 2023. PMID: 36441274
Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial.
Burmester GR, Buttgereit F, Bernasconi C, Álvaro-Gracia JM, Castro N, Dougados M, Gabay C, van Laar JM, Nebesky JM, Pethoe-Schramm A, Salvarani C, Donath MY, John MR; SEMIRA collaborators. Burmester GR, et al. Lancet. 2020 Jul 25;396(10246):267-276. doi: 10.1016/S0140-6736(20)30636-X. Lancet. 2020. PMID: 32711802 Clinical Trial.
Use of Janus kinase inhibitors before and after European Medicines Agency safety recommendations: a retrospective study.
Strunz PP, Risser LM, Englbrecht M, Witte T, Froehlich M, Schmalzing M, Gernert M, Hueper S, Bartz-Bazzanella P, von der Decken C, Karberg K, Gauler G, Späthling-Mestekemper S, Kuhn C, Vorbrüggen W, Welcker M, Kleinert S. Strunz PP, et al. Among authors: gauler g. Front Immunol. 2024 Aug 22;15:1445680. doi: 10.3389/fimmu.2024.1445680. eCollection 2024. Front Immunol. 2024. PMID: 39238648 Free PMC article.
Characteristics and outcomes of SARS-CoV-2 breakthrough infections among double-vaccinated and triple-vaccinated patients with inflammatory rheumatic diseases.
Hasseli R, Richter JG, Hoyer BF, Lorenz HM, Pfeil A, Regierer AC, Schmeiser T, Strangfeld A, Voll RE, Krause A, Reckert S, Gräßler A, Saar P, Kapelle A, Backhaus M, Blank N, Henes J, Osiek S, Knothe A, Hoese G, Brandt-Jürgens J, Maltzahn A, Specker C, Müller-Ladner U, Schulze-Koops H; COVID-19 task force of the German Society of Rheumatology collaborators; COVID19-Rheuma.de collaborators. Hasseli R, et al. RMD Open. 2023 Apr;9(2):e002998. doi: 10.1136/rmdopen-2023-002998. RMD Open. 2023. PMID: 37068915 Free PMC article.
Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial.
Gabay C, Emery P, van Vollenhoven R, Dikranian A, Alten R, Pavelka K, Klearman M, Musselman D, Agarwal S, Green J, Kavanaugh A; ADACTA Study Investigators. Gabay C, et al. Lancet. 2013 May 4;381(9877):1541-50. doi: 10.1016/S0140-6736(13)60250-0. Epub 2013 Mar 18. Lancet. 2013. PMID: 23515142 Clinical Trial.
17 results